Clinical Trial Update: Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients. [Phase 3]

View source ↗

Summary

Phase 3 trial update of Civacir, a polyclonal IgG, to prevent hepatitis C virus recurrence in liver transplant patients; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Hepatocellular Carcinoma
• Liver Cirrhosis
• Viral Hepatitis

Drugs mentioned

• Civacir (polyclonal immune globulin (IgG))

Snippet

Sponsor: Biotest Pharmaceuticals Corporation | Conditions: Hepatitis C Infection, Viruses | Phase 3 | Status: COMPLETED